Enhancement of specific cellular immune response induced by DNA vaccines encoding PML-RARα and hIL-2 genes

References

• Perego RA, Marenco P, Bianchi C et al. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission relapse and after bone marrow transplantation. Leukemia 1996; 10: 207–212.
   PubMed Web of Science ®Google Scholar
• Osman Y, Takahashi M, Zheng Z et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-Iympho-cytes: its applicability for antileukemia immunotherapy. Clin. Cancer Res 1999; 18: 485–492.
   Web of Science ®Google Scholar
• Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/ RARalpha and the leukemic stem cell. Leukemia 2004; 18: 1169–1175.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen S, Yang L et al. Clonal expanded TCR Vbeta T cells inpatients with APL. Hematology 2005; 10: 135–139.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369–1375.
   PubMed Web of Science ®Google Scholar
• Duncan C, Roddie H. Dendritic cell vaccines in acute leukaemia. Best Pract Res Clin Haematol 2008; 21: 521–541.
   PubMed Web of Science ®Google Scholar
• Dunussi-Joannopoulos K. Malignancy: gene therapy vaccines in acute myeloid leukemia: a need for clinical evaluation. Hematology 2000; 5: 103–115.
   PubMedGoogle Scholar
• Tonheim TC, Bogwald J, Dalmo RA. What happens to the DNAvaccine in fish? A review of current knowledge. Fish Shellfish Immunol 2008; 25: 1–18.
   PubMed Web of Science ®Google Scholar
• Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8± T cells. Cancer Immunol Immunother 2007; 56: 885–895.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62: 5845–5852.
   PubMed Web of Science ®Google Scholar
• Bocchia M, Wentworth PA, Southwood S et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680–2684.
   PubMed Web of Science ®Google Scholar
• Dermime S, Bertazzoli C, Marchesi E et al. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 1996; 2: 593–600.
   PubMed Web of Science ®Google Scholar
• Yu M, Finn OJ. DNA vaccines for cancer too. Cancer Immunol Immunother 2006; 55: 119–130.
   PubMed Web of Science ®Google Scholar
• Padua RA, Larghero J, Robin M et al. PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 2003; 9: 1413–1417.
   PubMed Web of Science ®Google Scholar
• Belakova J, Horynova M, Krupka M, Weigl E, Raska M. DNA vaccines: are they still just a powerful tool for the future? Arch Immunol Ther Exp ( Warsz) 2007; 55: 387–398.
   PubMed Web of Science ®Google Scholar
• Mencoboni MP, Tredici S, Varaldo M et al. Chemoimmunotherapy with low dose vinorelbine and interleu-kin-2 in treatment of patients with metastatic renal cell carcinoma. Neoplasma 2006; 53: 333–336.
   PubMed Web of Science ®Google Scholar
• Feurino LW, Fisher WE, Bharadwaj U, Yao Q, Chen C, Li M. Current update of cytokines in pancreatic cancer: pathogenic mechanisms, clinical indication, and therapeutic values. Cancer Invest 2006; 24: 696–703.
   PubMed Web of Science ®Google Scholar
• Stein AS, O'Donnell MR, Slovak ML et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J Clin Oncol 2003; 21: 615–623.
   PubMed Web of Science ®Google Scholar
• Sievers EL, Lange BJ, Sondel PM et al. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer J Sci Am 2000; 6(Suppl 1): S39–44.
   PubMedGoogle Scholar
• Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007; 25: 3731–3741.
   PubMed Web of Science ®Google Scholar
• Huehn J, Siegmund K, Lehmann JC et al. Developmental stage, phenotype, and migration distinguish naive- and effector/ memory-like CD4 ± regulatory T cells. J Exp Med 2004; 199: 303–313.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen S, Yang L et al. TRAV and TRBV repertoire, clonality and the proliferative history of umbilical cord blood T cells. Transplant Immunol 2007; 18: 151
   PubMed Web of Science ®Google Scholar
• Guinn BA, Mohamedali A, Thomas NS, Mills KI. Immuno-therapy of myeloid leukaemia. Cancer Immunol Immunother 2007; 56: 943–957.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595–601.
   PubMed Web of Science ®Google Scholar
• Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs 2000; 14: 299–318.
   PubMed Web of Science ®Google Scholar
• Niethammer AG, Xiang R, Ruehlmann JM et al. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res 2001; 61: 6178–6184.
   PubMed Web of Science ®Google Scholar
• Ribeiro RM, Perelson AS. Determining thymic output quantitatively: using models to interpret experimental T-cell receptor excision circle (TREC) data. Immunol Rev 2007; 216: 21–34.
   PubMed Web of Science ®Google Scholar
• Bertho JM, Demarquay C, Moulian N, van der Meeren A, Berrih-Aknin S, Gourmelon P. Phenotypic and immunohistological analyses of the human adult thymus: evidence for an active thymus during adult life. Cell Immunol 1997; 179: 30–40.
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Beal JA, Ruane PJ et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV + patients: a randomized controlled trial. HIV Clin Trials 2000; 1: 1–15.
   PubMedGoogle Scholar
• Marchetti G, Meroni L, Molteni C et al. Interleukin-2 immu-notherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS 2004; 18: 211–216.
   PubMed Web of Science ®Google Scholar
• Marchetti G, Meroni L, Varchetta S et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a rando-mized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 2002; 186: 606–616.
   PubMed Web of Science ®Google Scholar